Anixa Biosciences is trading 7.71% up at $3.31 in after-hours trading after updated survival observations from its ongoing Phase 1 lira-cel ovarian-cancer CAR-T trial.
- Multiple patients survived substantially beyond expected median survival, supporting investor interest in the therapy’s potential.
- The announcement follows recent progress to the highest dose level evaluated.
- Broader markets were weaker on September 4.